Hybrid LBA/LC-MS combines ligand binding assays with liquid chromatography-mass spectrometry physical detection. The result is a highly flexible assay that achieves the sensitivity of an immunoassay with the specificity and absolute quantification capability of mass spectrometry,within a single analytical workflow.
"},{"faq_question":"What modalities do hybrid LBA/LC-MS assays support?","faq_answer":"The hybrid approach has been applied to monoclonal antibodies,antibody-drug conjugates,vaccines,blood products,and therapeutic proteins. It can also quantify endogenous protein counterparts simultaneously with the biotherapeutic drug in the same run,which is relevant for programs where the endogenous protein shares structural features with the recombinant therapeutic. Matrix-matched calibrators support accurate quantification across both species.
"},{"faq_question":"How does it compare to a standard LBA?","faq_answer":"Standard ligand binding assays can be affected by matrix interference,anti-drug antibody cross-reactivity,and limited selectivity for closely related protein species. The hybrid approach adds an LC-MS/MS detection step after immunoaffinity capture,providing a dual-selection mechanism that improves specificity and reduces false signal. It also enables absolute quantification and characterization of post-translational modifications,which LBA alone cannot provide.
"}]}#-supreme-cellcarta-service-blocks-8-704{blocks-data:[{"image":"https://cellcarta.com/wp-content/uploads/2026/06/ELISA-Services-Hero-446.jpg","image_alt":"ELISA single-analyte biomarker quantification platform","title":"ELISA","description":"Quantify specific biomarkers with a well-established single-analyte assay at high throughput.","button_text":"Discover","button_url":"/capabilities/immunoassay-services/elisa/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-28-2-scaled.jpg","image_alt":"Meso Scale Discovery electrochemiluminescence multiplex platform","title":"Meso Scale Discovery® (MSD)","description":"Measure up to ten analytes in each plate well using serum or plasma samples as small as 25 μL.","button_text":"Discover","button_url":"/capabilities/immunoassay-services/meso-scale-discovery/","button_target":"_self"},{"image":"https://cellcarta.com/wp-content/uploads/2026/06/ADC-Solutions-Hero-676.jpg","image_alt":"Antibody-drug conjugate ADC precision assay platform","title":"Antibody-Drug Conjugates (ADC)","description":"Precision assays for target engagement,pharmacokinetics,and TME profiling.","button_text":"Discover","button_url":"/therapeutic-areas/modalities/antibody-drug-conjugates/","button_target":"_self"}]}#-supreme-cellcarta-tab-content-4-704{oxy-supreme-cellcarta-tab-content-content-heading-tag:h3;oxy-supreme-cellcarta-tab-content-content-heading-size:default;oxy-supreme-cellcarta-tab-content-content-body-size:default;tabs-data:[{"tab_title":"PK Assays","content_title":"","content_body":"Hybrid LBA/LC-MS approaches enable absolute quantification and PK characterization of complex biologics and drug products across a wide range of preclinical and clinical matrices.
\nCellCarta develops,qualifies,and validates hybrid assays under GCLP principles,enabling seamless transition from preclinical models to human sample analysis,accelerating timelines for regulatory-ready PK data.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Possible-Applications-23.jpg","image_alt":"Scientist performing PK assay using hybrid LBA/LC-MS platform"},{"tab_title":"Biomarker Quantification","content_title":"","content_body":"Hybrid LBA/LC-MS enables absolute and relative biomarker quantification,supporting flexible assay strategies. These approaches extend analysis to low-abundance targets in clinically complex matrices,allowing for biological pathway tracking throughout disease progression and therapeutic response.
\nHybrid LBA/LC-MS can quantify post-translational modifications (PTMs) directly in patient samples,providing a more complete picture of in vivo pharmacology.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Biomarker-Quantitation-Tab-88.jpg","image_alt":"Scientist quantifying protein biomarkers using mass spectrometry"},{"tab_title":"Rare Matrix Studies","tab_link_enabled":"","tab_link_url":"","tab_link_target":"_self","content_title":"","content_body":"Hybrid LBA/LC-MS has greater matrix flexibility and enables reduced dependency on antibody performance,which extends biomarker characterization to low-volume and rare matrices,including vitreous humor,aqueous humor,and cerebrospinal fluid.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/07/CellCarta_-18-2-1-scaled.jpg","image_alt":""},{"tab_title":"Immunogenicity","content_title":"","content_body":"Hybrid LBA/LC-MS extends anti-drug antibody (ADA) assessment beyond standalone LBAs by supporting ADA quantification and isotype characterization in a single analytical workflow.
","tab_image":"https://cellcarta.com/wp-content/uploads/2026/06/Immunogenicity-Tab-139.jpg","image_alt":"Scientist assessing immunogenicity using hybrid LBA/LC-MS assay"}]}